Characteristics of registered clinical trials for SARS-CoV-2 infection (n=201 trials)
| Clinical trial characteristics | Total trials (n=201) |
| Trial intervention, n (%) | |
| Drug | 188 (93.5) |
| Plasma | 13 (6.5) |
| Trial registry source, n (%) | |
| China | 100 (49.8) |
| USA | 76 (37.8) |
| Europe Union | 9 (4.5) |
| Iran | 10 (5.0) |
| Japan | 4 (2.0) |
| ISRCTN | 2 (1.0) |
| Status, n (%) | |
| Recruiting | 120 (59.7) |
| Not yet recruiting | 75 (37.3) |
| Withdrawn | 6 (3.0) |
| Recruitment country,* n (%) | |
| China | 126 (53.9) |
| Europe | 31 (13.3) |
| Asia (except China) | 18 (7.7) |
| North America | 17 (7.3) |
| Middle East | 13 (5.6) |
| South America | 6 (2.6) |
| Africa | 1 (0.4) |
| Not reported | 22 (9.4) |
| Phase, n (%) | |
| 0 | 37 (18.4) |
| 1 or 1/2 | 5 (2.5) |
| 2 | 32 (15.9) |
| 2/3 | 16 (8.0) |
| 3 | 33 (16.4) |
| 4 | 51 (24.9) |
| Not applicable | 26 (12.9) |
| Missing | 2 (1.0) |
| Lead sponsor, n (%) | |
| Hospitals | 111 (55.2) |
| Industry | 36 (17.9) |
| Government | 39 (19.4) |
| Other† | 7 (3.5) |
| Not reported | 8 (4.0) |
| Anticipated enrolment, n (%) | |
| Median (IQR) | 100 (50–240) |
| ≤50 | 54 (26.9) |
| 51–100 | 53 (26.4) |
| ≥100 | 94 (46.8) |
| Outcome,* n (%) | |
| Surrogate/biomarker | 85 (42.3) |
| Clinical scale | 33 (16.4) |
| Clinical outcome | 134 (66.7) |
Sources: WHO and ClinicalTrials.gov (as of 26 March 2020).
*Percentages may exceed 100% as categories are not mutually exclusive.
†Includes foundations and disease trial networks.
ISRCTN, International Standard Randomised Controlled Trial Number; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.